Empowered Patient Podcast

Karen Jagoda
  • 4.9 (18)
  • MEDICINE
  • UPDATED SEMIWEEKLY

Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.

  1. 12H AGO · BONUS

    Using Behavioral Science to Expand Clinical Trial Participation and Patient Engagement with Sarah Smith Oracle Life Sciences TRANSCRIPT

    Sarah Smith, Qualitative Specialist and Global Behavioral Science Strategy Lead at Oracle Life Sciences, is focused on the critical role of behavioral science in improving recruitment and retention in clinical trials.  Oracle Life Sciences is working to address historical underrepresentation in clinical trials by combining behavioral insights with integrated technologies to identify at-risk populations and understand barriers to participation. Using nudges to encourage trial participation, conducting decentralized trials, and applying AI to reshape patient engagement are strong tools for building trust and improving accessibility. Sarah explains, "Behavioral science is about understanding behavior. It draws from a number of disciplines like psychology, anthropology, and behavioral economics. But what it tells us is that people aren't rational. They don't always do the things that we expect them to do. So if we want to engage people, if we want to engage them properly, if we want to ensure that all the things we do are equitable and have an equal playing field, then we need to really understand why people do the things they do and to try and help us make sense of that in a way that encompasses everybody."   "We see treatment and technology advancing, but there are many communities that aren't part of that still, that are underrepresented. Factors like gender, ethnicity, culture, conditions that carry a stigma, socioeconomic issues, and geographic limitations - all of these things can limit the opportunity, ability, and willingness of individuals to participate in clinical trials. And that means the impact of those trials is less generalizable because those people are not represented. They're just simply not there. So the treatment that is aimed at these people is not measured in those groups. Oracle is working to address this by combining a deeper understanding of behavior with integrated technology to try to close this gap in representation to give more inclusive patient-centered care that unifies clinical, behavioral, and safety data across settings. To give a more holistic view, to give more coordinated care, to identify risks earlier, to identify patients that perhaps just need a bit more attention - a more personalized engagement."   #OracleLifeSciences #lifesciences #ClinicalResearch #PatientCentricity #PatientEngagement #ClinicalTrials #Healthliteracy #BehavioralScience #HealthEquity #AI #Healthcare #Diversity #Inclusion #MedicalResearch #Innovation Oracle.com/life-sciences  Listen to the podcast here

  2. 12H AGO

    Using Behavioral Science to Expand Clinical Trial Participation and Patient Engagement with Sarah Smith Oracle Life Sciences

    Sarah Smith, Qualitative Specialist and Global Behavioral Science Strategy Lead at Oracle Life Sciences, is focused on the critical role of behavioral science in improving recruitment and retention in clinical trials.  Oracle Life Sciences is working to address historical underrepresentation in clinical trials by combining behavioral insights with integrated technologies to identify at-risk populations and understand barriers to participation. Using nudges to encourage trial participation, conducting decentralized trials, and applying AI to reshape patient engagement are strong tools for building trust and improving accessibility. Sarah explains, "Behavioral science is about understanding behavior. It draws from a number of disciplines like psychology, anthropology, and behavioral economics. But what it tells us is that people aren't rational. They don't always do the things that we expect them to do. So if we want to engage people, if we want to engage them properly, if we want to ensure that all the things we do are equitable and have an equal playing field, then we need to really understand why people do the things they do and to try and help us make sense of that in a way that encompasses everybody."   "We see treatment and technology advancing, but there are many communities that aren't part of that still, that are underrepresented. Factors like gender, ethnicity, culture, conditions that carry a stigma, socioeconomic issues, and geographic limitations - all of these things can limit the opportunity, ability, and willingness of individuals to participate in clinical trials. And that means the impact of those trials is less generalizable because those people are not represented. They're just simply not there. So the treatment that is aimed at these people is not measured in those groups. Oracle is working to address this by combining a deeper understanding of behavior with integrated technology to try to close this gap in representation to give more inclusive patient-centered care that unifies clinical, behavioral, and safety data across settings. To give a more holistic view, to give more coordinated care, to identify risks earlier, to identify patients that perhaps just need a bit more attention - a more personalized engagement."   #OracleLifeSciences #lifesciences #ClinicalResearch #PatientCentricity #PatientEngagement #ClinicalTrials #Healthliteracy #BehavioralScience #HealthEquity #AI #Healthcare #Diversity #Inclusion #MedicalResearch #Innovation Oracle.com/life-sciences  Download the transcript here

    20 min

  3. 4D AGO · BONUS

    Using Deep Brain Stimulation for Treatment-Resistant Depression with Dr. Josh Eloge Connected Neuroscience TRANSCRIPT

    Dr. Josh Eloge, Associate Director for the Woman's Board Treatment Research Center, Assistant Professor of Psychiatry and Behavioral Sciences at the Rush University Medical Center, and Founder of Connected Neuroscience has a focus on treatment-resistant depression which is defined as depression that is not relieved by at least two first-line medications. Research has identified that TRD is associated with hyperactivity in a specific brain region, shifting attention from a chemical view of depression to a neurobiological one.  Research on deep-brain stimulation and implantable technology is demonstrating neuromodulation and reductions in hyperactivity. Josh explains, "So depression, kind of a low mood, is something that is universally experienced, right? It's part of the human condition to a certain extent. However, when a low mood persists for most of the time and is accompanied by problems with being able to enjoy things, disruptions in sleep, appetite, or even thoughts about life not being worth living, one might be experiencing something called a major depressive episode, part of a major depressive disorder. And this is a specific psychiatric disorder that requires attention. Frankly, there are poor outcomes associated with this. About one in five Americans will experience a major depressive episode at some time in their life, so it's a little bit more common than people might think, and there are some effective treatments. So in my work, both seeing patients and in the research that I do here at Rush, we're looking at major depressive episode and trying to think how can we best treat this disorder to get people back to being able to enjoy things that they like to do, being with their family, have meaningful work, these sorts of things." "However, the research also shows that about a third of patients who try these different medications don't ultimately get the response that we are hoping for. And this has been termed treatment-resistant depression - when you try at least two of these first-line medications, but the symptoms are still present, and this is where a lot of the research that we've been working on in this specific population has been focused on." #ConnectedNeuroscience #MentalHealth #Neuroscience #DeepBrainStimulation #TreatmentResistantDepression #MedicalResearch #Innovation #RushUniversity #BrainHealth #ClinicalTrials #Psychiatry #NeuroModulation #DBS #TRANSCENDstudy #TRD connectedneuroscience.com  Listen to the podcast here

  4. 4D AGO

    Using Deep Brain Stimulation for Treatment-Resistant Depression with Dr. Josh Eloge Connected Neuroscience

    Dr. Josh Eloge, Associate Director for the Woman's Board Treatment Research Center, Assistant Professor of Psychiatry and Behavioral Sciences at the Rush University Medical Center, and Founder of Connected Neuroscience has a focus on treatment-resistant depression which is defined as depression that is not relieved by at least two first-line medications. Research has identified that TRD is associated with hyperactivity in a specific brain region, shifting attention from a chemical view of depression to a neurobiological one.  Research on deep-brain stimulation and implantable technology is demonstrating neuromodulation and reductions in hyperactivity. Josh explains, "So depression, kind of a low mood, is something that is universally experienced, right? It's part of the human condition to a certain extent. However, when a low mood persists for most of the time and is accompanied by problems with being able to enjoy things, disruptions in sleep, appetite, or even thoughts about life not being worth living, one might be experiencing something called a major depressive episode, part of a major depressive disorder. And this is a specific psychiatric disorder that requires attention. Frankly, there are poor outcomes associated with this. About one in five Americans will experience a major depressive episode at some time in their life, so it's a little bit more common than people might think, and there are some effective treatments. So in my work, both seeing patients and in the research that I do here at Rush, we're looking at major depressive episode and trying to think how can we best treat this disorder to get people back to being able to enjoy things that they like to do, being with their family, have meaningful work, these sorts of things." "However, the research also shows that about a third of patients who try these different medications don't ultimately get the response that we are hoping for. And this has been termed treatment-resistant depression - when you try at least two of these first-line medications, but the symptoms are still present, and this is where a lot of the research that we've been working on in this specific population has been focused on." #ConnectedNeuroscience #MentalHealth #Neuroscience #DeepBrainStimulation #TreatmentResistantDepression #MedicalResearch #Innovation #RushUniversity #BrainHealth #ClinicalTrials #Psychiatry #NeuroModulation #DBS #TRANSCENDstudy #TRD connectedneuroscience.com Download the transcript here

    20 min

  5. 5D AGO · BONUS

    Addressing Health Disparities Through Workforce Diversity and Improved Access to Clinical Trials with Dr. Eugene Manley STEMM & Cancer Health Equity Foundation TRANSCRIPT

    Dr. Eugene Manley, biomedical scientist turned social impact leader and Founder and CEO of the STEMM & Cancer Health Equity Foundation,  is focused on increasing STEMM workforce diversity and improving outcomes for underserved cancer patients. He highlights the lack of diversity in foundational lung cancer research and the need to expand the number of cell lines being included to develop more effective therapies. Eugene also raises concerns about barriers to clinical trial participation and the need to engage local community partners and AI to raise awareness and improve accessibility. Eugene explains, "The SCHEQ Foundation, which is a short name for STEMM and Cancer Health Equity, is tasked with working to increase STEMM workforce diversity and improve outcomes for underserved patients navigating the cancer care continuum. This is done broadly through trying to increase STEMM access and exposure, mentorship and training programs to help students navigate career transitions, and providing information and resources to underserved patients to help them navigate and access the care they're entitled to." "There are many paths into the medical field now. If you're trying to do particularly applied research or do things that directly impact patient outcomes, then yes, you might want to go more of a technical path. But as we mentioned, AI is the new thing on the block. It's a lot of looking at trends, variances, and differences in data, and then you can use that to predict how things may act or behave. However, the downside of this is that the data is often based on one population, one race, or ethnicity, which makes it harder to broadly generalize these results. So that's a lot of the challenges that we're seeing right now." #SCHEQ #HealthEquity #STEMM #CancerResearch #DiversityInScience #BiomedicalResearch #ClinicalTrials #LungCancer #HealthDisparities #MedicalInnovation #SocialImpact #HealthcareAccess #PrecisionMedicine scheq.org Listen to the podcast here

  6. 5D AGO

    Addressing Health Disparities Through Workforce Diversity and Improved Access to Clinical Trials with Dr. Eugene Manley STEMM & Cancer Health Equity Foundation

    Dr. Eugene Manley, biomedical scientist turned social impact leader and Founder and CEO of the STEMM & Cancer Health Equity Foundation,  is focused on increasing STEMM workforce diversity and improving outcomes for underserved cancer patients. He highlights the lack of diversity in foundational lung cancer research and the need to expand the number of cell lines being included to develop more effective therapies. Eugene also raises concerns about barriers to clinical trial participation and the need to engage local community partners and AI to raise awareness and improve accessibility. Eugene explains, "The SCHEQ Foundation, which is a short name for STEMM and Cancer Health Equity, is tasked with working to increase STEMM workforce diversity and improve outcomes for underserved patients navigating the cancer care continuum. This is done broadly through trying to increase STEMM access and exposure, mentorship and training programs to help students navigate career transitions, and providing information and resources to underserved patients to help them navigate and access the care they're entitled to." "There are many paths into the medical field now. If you're trying to do particularly applied research or do things that directly impact patient outcomes, then yes, you might want to go more of a technical path. But as we mentioned, AI is the new thing on the block. It's a lot of looking at trends, variances, and differences in data, and then you can use that to predict how things may act or behave. However, the downside of this is that the data is often based on one population, one race, or ethnicity, which makes it harder to broadly generalize these results. So that's a lot of the challenges that we're seeing right now." #SCHEQ #HealthEquity #STEMM #CancerResearch #DiversityInScience #BiomedicalResearch #ClinicalTrials #LungCancer #HealthDisparities #MedicalInnovation #SocialImpact #HealthcareAccess #PrecisionMedicine scheq.org Download the transcript here

    20 min

  7. 6D AGO · BONUS

    How Community-Based Clinical Trials Can Transform Patient Access and Participation with Ro Wickramasinghe Pi Health TRANSCRIPT

    Ro Wickramasinghe, Vice President and Head of Global Business at Pi Health, identifies fundamental problems plaguing clinical trials, including operational inefficiencies and limited access to trials. Pi Health is addressing these challenges by developing an integrated software platform for clinical trial sponsors, sites, and patients and partnering with community-based cancer treatment centers worldwide.  The company has built a hospital in India to serve as a living laboratory to test and refine its model to democratize access and increase the ethnic diversity of trial participants.  Ro explains, "I think the challenge has always been, from a pharma-biotech perspective, is to find patients, but, from the other perspective, its patients participating in trials and being able to find clinical trials. So a lot of stats get bandied around, but despite many eligible patients, the percentage of eligible patients who actually end up in a clinical trial is really small. It's like 5% to 8%, so not a huge amount. I think that's kind of one problem."  "So we have it in chicken and egg scenario where we as a company develop clinical trial software, but when ultimately the vision for us is for that to really become the standard of care and really make trials more efficient for the clinicians that treat the patients and run the trials for these pharma companies and biotech companies that develop the drugs and sponsor the study."  "But having said that, I think to run lots of studies, what we decided to do was to build our own cancer hospital in India. And the beauty of that is that it is fully vertically integrated at the point of care. So the data gets captured on those patients in FICS, which is the software we've developed and then we can run trials. We have run trials for pharma and biotech at that site using our software. So it was, I guess, one of the quicker ways to test the software in a real-world environment and also getting lots of data on FICS and how it can benefit patients from the point of care to being on trials."  #PiHealth #ClinicalTrials #HealthTech #CancerResearch #Innovation #DigitalHealth #PharmaTech #PatientAccess #MedTech #Healthcare #ClinicalResearch #GlobalHealth #HealthcareInnovation #India Pihealth.ai Listen to the podcast here

  8. 6D AGO

    How Community-Based Clinical Trials Can Transform Patient Access and Participation with Ro Wickramasinghe Pi Health

    Ro Wickramasinghe, Vice President and Head of Global Business at Pi Health, identifies fundamental problems plaguing clinical trials, including operational inefficiencies and limited access to trials. Pi Health is addressing these challenges by developing an integrated software platform for clinical trial sponsors, sites, and patients and partnering with community-based cancer treatment centers worldwide.  The company has built a hospital in India to serve as a living laboratory to test and refine its model to democratize access and increase the ethnic diversity of trial participants.  Ro explains, "I think the challenge has always been, from a pharma-biotech perspective, is to find patients, but, from the other perspective, its patients participating in trials and being able to find clinical trials. So a lot of stats get bandied around, but despite many eligible patients, the percentage of eligible patients who actually end up in a clinical trial is really small. It's like 5% to 8%, so not a huge amount. I think that's kind of one problem."  "So we have it in chicken and egg scenario where we as a company develop clinical trial software, but when ultimately the vision for us is for that to really become the standard of care and really make trials more efficient for the clinicians that treat the patients and run the trials for these pharma companies and biotech companies that develop the drugs and sponsor the study."  "But having said that, I think to run lots of studies, what we decided to do was to build our own cancer hospital in India. And the beauty of that is that it is fully vertically integrated at the point of care. So the data gets captured on those patients in FICS, which is the software we've developed and then we can run trials. We have run trials for pharma and biotech at that site using our software. So it was, I guess, one of the quicker ways to test the software in a real-world environment and also getting lots of data on FICS and how it can benefit patients from the point of care to being on trials."  #PiHealth #ClinicalTrials #HealthTech #CancerResearch #Innovation #DigitalHealth #PharmaTech #PatientAccess #MedTech #Healthcare #ClinicalResearch #GlobalHealth #HealthcareInnovation #India Pihealth.ai Download the transcript here

    19 min
See All (2K)

4.9
out of 5
18 Ratings

About

Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.

Information